Trial document





This trial has been registered retrospectively.
drksid header

  DRKS00000012

Trial Description

start of 1:1-Block title

Title

Prospektive, randomisized, double-blind, placebo-controlled multicenter phase III-study to evaluate the efficacy of octreotide in patients with inoperable hepatocellular carcinoma

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

Hector-Studie

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

[---]*

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

A preliminary study has shown that the hormone-similar, growth-retarding drug octreotide can prolong survival time in patients with primary liver cancer. Due to methodological deficiencies of the preliminary study the results will be re-checked by the comparison of Octreotid with an pseudo-drug (so-called placebo) primarily regarding to the survival time and secondarily concerning costs, side effects, patient cooperation and quality of life as well as specific conditions in the tumor tissue in both groups with 108 patients with primary liver cancer.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

A pilot study showed that Octreotid can prolong survival time of patients with HCC. Due to methodological deficiencies the results of this pilot study will be re-evalueted by comparison of Octreotid versus placebo primarily regarding to the global survival time and secondarily concerning the costs, side effects, patient compliance and quality of life as well as the Somatostatin receptors in the tumor tissue and its prognostic relevance in both groups with 108 patients with hepatozellular carcinoma.
An interim analysis was done after occurrence of the half of the events (deaths). No significant effect could be shown.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00000012
  •   2008/09/05
  •   2005/09/14
  •   no
  •   Approved
  •   240/98, Ethik-Kommission der Albert-Ludwig-Universität Freiburg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   NCT00386984  (ClinicalTrials.gov)
  •   UKF000513  (Register Klinischer Studien des Universitätsklinikums Freiburg)
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   C22.0 -  Malignant neoplasm: Liver cell carcinoma
  •   Liver Neoplasms
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Somatostatin (octreotide)
  •   pseudo-drug (so called placebo)
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Interventional
  •   [---]*
  •   Randomized controlled trial
  •   Double or multiple blind
  •   [---]*
  •   Placebo
  •   Treatment
  •   Parallel
  •   III
  •   [---]*
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Overall survival time

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

[---]*

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • [---]*
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   1999/10/01
  •   120
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

Inoperable patients with histologically approved HCC or patients who refuse surgery and who otherwise (e.g. due to the advanced tumor stage) are not applicable for palliative local therapy (e.g. PEI, TACE, RFTA). The inoperability should be approved by an experienced (transplantation) surgeon and dokumented.
Age: no restriction.

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

General
- Patient with symptomatic Cholecysto-/Choledocholithiasis
- Patient with severe psychiatric disease.
- Participation in another clinical trial within the last 4 weeks.
- Simultaneous participation in another clinical examination.
- Legally incapacitated patient, who is not able, to understand nature, meaning and consequence of the study.
- Continuous drug or alcohol abuse.
- Patient with known HIV infection and antiretrovirale therapy.
- Patient with not controllable infection disease.
- Pregnancy.

Study- and indication-specific exclusion criteria
- Secondary malignoma without complete remission.
- Secondary malignoma with complete remission but current adjuvante therapy.
- Preliminary or current therapy with tamoxiphene
- Pretreatment of the HCC.
- First-time diagnosis > 6 months before inclusion into the study.
- Severe hepatic encephalopathy, refractory to any treatment.
- Patients with operable HCC.
- Contraindication to i.m. injections.
- Hypersensitivity to octreotide.

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Gastro-enterologische Abteilung des Universitätsklinikums Freiburg
    • Hugstetter Str. 55
    • 79106  Freiburg
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • Evangelisches Diakoniekrankenhaus
    • Mr.  Prof. Dr. med.  Hans-Peter  Allgaier 
    • Germany
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact scientific-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Novartis Deutschland
    • Roonstraße 25
    • 90429  Nürnberg
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   +49 911 27312940
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
  • start of 1:1-Block address otherSupport
    • Deutsche Krebshilfe e.V.
    • Buschstr. 32
    • 53113  Bonn
    • Germany
    end of 1:1-Block address otherSupport
    start of 1:1-Block address contact otherSupport
    end of 1:1-Block address contact otherSupport
  • start of 1:1-Block address otherSupport
    • Bundesministerium für Bildung und Forschung
    end of 1:1-Block address otherSupport
    start of 1:1-Block address contact otherSupport
    end of 1:1-Block address contact otherSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting complete, follow-up complete
  •   2003/02/28
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

  •   Allgaier HP, Becker G, Blum HE. [A therapeutic study of hepatocellular carcinoma using octreotide (HECTOR). Hepatocellular Carcinoma: Treatment with Octreotide] Dtsch Med Wochenschr. 2000 Mar 17;125(11):320. German. No abstract available.
end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.